Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need.
Madrigal recognizes that compounds with greater selectivity for thyroid hormone receptor (THR)- and liver uptake has the greatest potential to overcome challenges faced by prior, less selective compounds and deliver the full therapeutic potential of THR- agonism.The Company believes that resmetirom, its lead product candidate, is the first orally administered, small-molecule, liver-directed, truly -selective THR agonist.
Madrigal recognizes that compounds with greater selectivity for thyroid hormone receptor (THR)- and liver uptake has the greatest potential to overcome challenges faced by prior, less selective compounds and deliver the full therapeutic potential of THR- agonism.The Company believes that resmetirom, its lead product candidate, is the first orally administered, small-molecule, liver-directed, truly -selective THR agonist.
Services
He currently works as an independent consultant. From 2002 to 2005, Mr. Bate served as head of commercial operations and chief financial officer at Millennium Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining Millennium Pharmaceuticals, Mr. Bate co-founded JSB Partners, LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies.
Preclinical, toxicology, Phase 1, and Phase 2 clinical data suggest resmetirom has an attractive, differentiated profile as a potential treatment for non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD) and associated dyslipidemias. THR- selectivity also enhances the safety profile of resmetirom, compared to non-selective agents.
Reviews
Be the first to review Madrigal Pharmaceuticals.
Write a Review
